title: Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy.
authors.forename: Melanie
authors.initials: M
authors.lastname: Hoch
authors.forename: Denise
authors.initials: D
authors.lastname: Hilfiker-Kleiner
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006333:Heart Failure / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D012306:Risk
chemical_list: D000970:Antineoplastic Agents; D004921:Erythropoietin
references.citation: Circ Res. 2004 Jul 23;95(2):187-95
references.pmid: 15192020
references.citation: Cell Stem Cell. 2011 Aug 5;9(2):131-43
references.pmid: 21816364
references.citation: Curr Med Chem. 2011;18(26):4012-8
references.pmid: 21824090
references.citation: Anticancer Drugs. 2005 Jul;16(6):601-7
references.pmid: 15930886
references.citation: Cell. 2007 Feb 9;128(3):589-600
references.pmid: 17289576
references.citation: J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
references.pmid: 20117401
references.citation: Nat Med. 2007 Aug;13(8):970-4
references.pmid: 17660827